Trade Surface Oncology - SURF CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Surface Oncology Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.05 |
Open* | 1.02 |
1-Year Change* | -21.54% |
Day's Range* | 0.99 - 1.05 |
52 wk Range | 0.56-1.43 |
Average Volume (10 days) | 466.36K |
Average Volume (3 months) | 16.51M |
Market Cap | 65.08M |
P/E Ratio | -100.00K |
Shares Outstanding | 60.82M |
Revenue | N/A |
EPS | -1.54 |
Dividend (Yield %) | N/A |
Beta | 1.74 |
Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 7, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.05 | 0.99 |
Sep 6, 2023 | 1.05 | 0.07 | 7.14% | 0.98 | 1.08 | 0.98 |
Sep 5, 2023 | 0.99 | -0.06 | -5.71% | 1.05 | 1.05 | 0.98 |
Sep 1, 2023 | 1.06 | 0.02 | 1.92% | 1.04 | 1.08 | 1.02 |
Aug 31, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.06 | 1.01 |
Aug 30, 2023 | 1.04 | 0.02 | 1.96% | 1.02 | 1.06 | 1.02 |
Aug 29, 2023 | 1.03 | 0.07 | 7.29% | 0.96 | 1.04 | 0.96 |
Aug 28, 2023 | 0.98 | 0.03 | 3.16% | 0.95 | 0.98 | 0.92 |
Aug 25, 2023 | 0.93 | 0.02 | 2.20% | 0.91 | 0.93 | 0.91 |
Aug 24, 2023 | 0.93 | 0.02 | 2.20% | 0.91 | 0.93 | 0.89 |
Aug 23, 2023 | 0.92 | 0.00 | 0.00% | 0.92 | 0.96 | 0.92 |
Aug 22, 2023 | 0.89 | -0.01 | -1.11% | 0.90 | 0.92 | 0.87 |
Aug 21, 2023 | 0.90 | 0.02 | 2.27% | 0.88 | 0.92 | 0.87 |
Aug 18, 2023 | 0.88 | 0.05 | 6.02% | 0.83 | 0.89 | 0.83 |
Aug 17, 2023 | 0.86 | -0.02 | -2.27% | 0.88 | 0.89 | 0.85 |
Aug 16, 2023 | 0.88 | -0.01 | -1.12% | 0.89 | 0.90 | 0.88 |
Aug 15, 2023 | 0.89 | 0.01 | 1.14% | 0.88 | 0.89 | 0.86 |
Aug 14, 2023 | 0.88 | -0.02 | -2.22% | 0.90 | 0.91 | 0.87 |
Aug 11, 2023 | 0.91 | -0.01 | -1.09% | 0.92 | 0.92 | 0.90 |
Aug 10, 2023 | 0.92 | 0.02 | 2.22% | 0.90 | 0.94 | 0.90 |
Surface Oncology Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 7, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Surface Oncology Inc Earnings Release Q4 2023 Surface Oncology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 30 | 2.687 | 126.162 | 15.36 | 59.417 |
Revenue | 30 | 2.687 | 126.162 | 15.36 | 59.417 |
Total Operating Expense | 91.869 | 78.7 | 66.825 | 70.149 | 66.014 |
Selling/General/Admin. Expenses, Total | 27.635 | 27.769 | 25.669 | 23.627 | 16.076 |
Research & Development | 64.234 | 50.931 | 38.907 | 49.099 | 52.492 |
Interest Expense (Income) - Net Operating | 2.249 | -2.577 | -2.554 | ||
Operating Income | -61.869 | -76.013 | 59.337 | -54.789 | -6.597 |
Net Income Before Taxes | -63.586 | -78.485 | 59.337 | -54.789 | -6.597 |
Net Income After Taxes | -63.586 | -78.485 | 59.337 | -54.789 | -6.597 |
Net Income Before Extra. Items | -63.586 | -78.485 | 59.337 | -54.789 | -6.597 |
Net Income | -63.586 | -78.485 | 59.337 | -54.789 | -6.597 |
Total Adjustments to Net Income | 0 | 0 | -0.011 | ||
Income Available to Common Excl. Extra. Items | -63.586 | -78.485 | 59.337 | -54.789 | -6.608 |
Income Available to Common Incl. Extra. Items | -63.586 | -78.485 | 59.337 | -54.789 | -6.608 |
Diluted Net Income | -63.586 | -78.485 | 59.337 | -54.789 | -6.608 |
Diluted Weighted Average Shares | 55.7614 | 44.2433 | 38.1418 | 27.8549 | 19.9908 |
Diluted EPS Excluding Extraordinary Items | -1.14032 | -1.77394 | 1.5557 | -1.96694 | -0.33055 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -1.14032 | -1.77394 | 1.5557 | -1.96691 | -0.32985 |
Interest Income (Expense), Net Non-Operating | -3.146 | -2.546 | |||
Other, Net | 1.429 | 0.074 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 25.641 | 19.663 | 21.184 | 22.898 | 24.624 |
Selling/General/Admin. Expenses, Total | 8.576 | 5.886 | 5.896 | 6.004 | 6.426 |
Research & Development | 13.831 | 13.777 | 15.288 | 16.894 | 18.198 |
Operating Income | -25.641 | -19.663 | -21.184 | -22.898 | -24.624 |
Interest Income (Expense), Net Non-Operating | -3.108 | -0.932 | -0.902 | -0.829 | -0.733 |
Other, Net | 0.557 | 0.854 | 0.754 | 0.487 | 0.144 |
Net Income Before Taxes | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Net Income After Taxes | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Net Income Before Extra. Items | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Net Income | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Income Available to Common Excl. Extra. Items | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Income Available to Common Incl. Extra. Items | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Diluted Net Income | -28.192 | -19.741 | -21.332 | -23.24 | -25.213 |
Diluted Weighted Average Shares | 60.7179 | 60.628 | 60.6154 | 59.0545 | 54.6548 |
Diluted EPS Excluding Extraordinary Items | -0.46431 | -0.32561 | -0.35192 | -0.39353 | -0.46131 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.41105 | -0.32561 | -0.35192 | -0.39353 | -0.46131 |
Dilution Adjustment | |||||
Unusual Expense (Income) | 3.234 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 129.14 | 157.346 | 180.509 | 107.926 | 164.601 |
Cash and Short Term Investments | 124.823 | 154.149 | 175.141 | 105.161 | 158.835 |
Cash & Equivalents | 50.91 | 56.045 | 175.141 | 46.755 | 82.912 |
Short Term Investments | 73.913 | 98.104 | 0 | 58.406 | 75.923 |
Total Receivables, Net | 0.197 | 0.765 | 2.571 | 0.336 | 1.246 |
Prepaid Expenses | 4.12 | 2.432 | 2.797 | 2.429 | 4.52 |
Other Current Assets, Total | 0 | ||||
Total Assets | 159.91 | 190.847 | 217.138 | 131.693 | 174.065 |
Property/Plant/Equipment, Total - Net | 29.173 | 31.521 | 34.575 | 22.144 | 8.226 |
Property/Plant/Equipment, Total - Gross | 38.29 | 39.274 | 40.759 | 26.658 | 10.959 |
Accumulated Depreciation, Total | -9.117 | -7.753 | -6.184 | -4.514 | -2.733 |
Other Long Term Assets, Total | 1.597 | 1.98 | 2.054 | 1.623 | 1.238 |
Total Current Liabilities | 16.26 | 20.023 | 17.651 | 19.274 | 27.177 |
Accounts Payable | 0.256 | 1.55 | 1.674 | 3.384 | 3.412 |
Accrued Expenses | 13.858 | 15.235 | 14.929 | 10.22 | 8.263 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.146 | 3.238 | 1.048 | 5.67 | 15.502 |
Total Liabilities | 66.507 | 71.947 | 61.391 | 75.027 | 71.203 |
Total Long Term Debt | 25.585 | 25.015 | 14.759 | 5.109 | 0 |
Other Liabilities, Total | 24.662 | 26.909 | 28.981 | 50.644 | 44.026 |
Total Equity | 93.403 | 118.9 | 155.747 | 56.666 | 102.862 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.006 | 0.005 | 0.004 | 0.003 | 0.003 |
Additional Paid-In Capital | 298.741 | 259.859 | 218.001 | 178.155 | 169.784 |
Retained Earnings (Accumulated Deficit) | -204.329 | -140.743 | -62.258 | -121.595 | -66.806 |
Other Equity, Total | -1.015 | -0.221 | 0 | 0.103 | -0.119 |
Total Liabilities & Shareholders’ Equity | 159.91 | 190.847 | 217.138 | 131.693 | 174.065 |
Total Common Shares Outstanding | 60.579 | 46.9588 | 40.7071 | 27.8933 | 27.7726 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Long Term Debt | 25.585 | 25.015 | 14.759 | 5.109 | |
Accounts Receivable - Trade, Net | 0 | 0.518 | 2.571 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 107.209 | 129.14 | 150.122 | 161.505 | 184.285 |
Cash and Short Term Investments | 102.055 | 124.823 | 146.35 | 156.648 | 150.393 |
Cash & Equivalents | 28.982 | 50.91 | 65.096 | 74.824 | 65.657 |
Short Term Investments | 73.073 | 73.913 | 81.254 | 81.824 | 84.736 |
Prepaid Expenses | 5.154 | 4.317 | 3.772 | 4.857 | 3.892 |
Total Assets | 137.008 | 159.91 | 181.621 | 193.979 | 217.68 |
Property/Plant/Equipment, Total - Net | 28.204 | 29.173 | 29.813 | 30.651 | 31.395 |
Other Long Term Assets, Total | 1.595 | 1.597 | 1.686 | 1.823 | 2 |
Total Current Liabilities | 14.75 | 16.26 | 17.992 | 19.725 | 19.561 |
Accounts Payable | 1.108 | 0.256 | 0.535 | 0.486 | 2.625 |
Accrued Expenses | 10.423 | 16.004 | 17.457 | 16.447 | 16.223 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 3.219 | 0 | 2.792 | 0.713 | |
Total Liabilities | 61.177 | 66.507 | 68.802 | 68.263 | 70.693 |
Total Long Term Debt | 22.488 | 25.585 | 25.462 | 22.519 | 24.448 |
Long Term Debt | 22.488 | 25.585 | 25.462 | 22.519 | 24.448 |
Other Liabilities, Total | 23.939 | 24.662 | 25.348 | 26.019 | 26.684 |
Total Equity | 75.831 | 93.403 | 112.819 | 125.716 | 146.987 |
Redeemable Preferred Stock | |||||
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
Additional Paid-In Capital | 300.464 | 298.741 | 297.179 | 286.637 | 282.436 |
Retained Earnings (Accumulated Deficit) | -224.07 | -204.329 | -182.997 | -159.757 | -134.544 |
Other Equity, Total | -0.569 | -1.015 | -1.369 | -1.17 | -0.911 |
Total Liabilities & Shareholders’ Equity | 137.008 | 159.91 | 181.621 | 193.979 | 217.68 |
Total Common Shares Outstanding | 60.7169 | 60.579 | 60.5423 | 55.3849 | 54.3476 |
Total Receivables, Net | 0 | 30 | |||
Accounts Receivable - Trade, Net | 0 | 30 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -63.586 | -78.485 | 59.337 | -54.789 | -6.597 |
Cash From Operating Activities | -59.552 | -62.344 | 29.997 | -60.14 | -13.222 |
Cash From Operating Activities | 1.368 | 1.569 | 1.67 | 1.785 | 1.347 |
Non-Cash Items | 10.254 | 12.463 | 11.319 | 7.116 | 4.854 |
Cash Taxes Paid | 0 | 0 | 0.028 | ||
Changes in Working Capital | -7.588 | 2.109 | -42.329 | -14.252 | -12.826 |
Cash From Investing Activities | 22.757 | -99.252 | 58.307 | 16.965 | -36.584 |
Capital Expenditures | -0.497 | -0.12 | -0.043 | -1.538 | -2.019 |
Other Investing Cash Flow Items, Total | 23.254 | -99.132 | 58.35 | 18.503 | -34.565 |
Cash From Financing Activities | 31.66 | 42.5 | 40.082 | 7.415 | 110.376 |
Financing Cash Flow Items | 0 | 9.469 | |||
Issuance (Retirement) of Stock, Net | 31.66 | 31.813 | 30.082 | 0.279 | 100.907 |
Issuance (Retirement) of Debt, Net | 0 | 10.687 | 10 | 7.136 | 0 |
Net Change in Cash | -5.135 | -119.096 | 128.386 | -35.76 | 60.57 |
Cash Interest Paid | 2.476 | 1.406 | 1.052 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -19.741 | -63.586 | -42.254 | -19.014 | 6.199 |
Cash From Operating Activities | -23.439 | -59.552 | -37.798 | -18.971 | -23.566 |
Cash From Operating Activities | 0.318 | 1.368 | 1.037 | 0.691 | 0.345 |
Non-Cash Items | 2.251 | 10.254 | 8.153 | 5.682 | 2.803 |
Cash Interest Paid | 1.746 | 2.476 | 1.746 | 1.097 | 0.531 |
Changes in Working Capital | -6.267 | -7.588 | -4.734 | -6.33 | -32.913 |
Cash From Investing Activities | 1.434 | 22.757 | 15.232 | 14.909 | 12.465 |
Capital Expenditures | -0.017 | -0.497 | -0.205 | -0.146 | -0.035 |
Other Investing Cash Flow Items, Total | 1.451 | 23.254 | 15.437 | 15.055 | 12.5 |
Cash From Financing Activities | 0.077 | 31.66 | 31.617 | 22.841 | 20.713 |
Issuance (Retirement) of Stock, Net | 0.077 | 31.66 | 31.617 | 22.841 | 20.713 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Net Change in Cash | -21.928 | -5.135 | 9.051 | 18.779 | 9.612 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Surface Oncology Company profile
About Surface Oncology Inc
Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Surface Oncology Inc revenues decreased 98% to $2.7M. Net loss totaled $78.5M vs. income of $59.3M. Revenues reflect License-related revenue decrease of 97% to $2.7M, Collaboration revenue - related party decrease from $38.6M to $0K. Net loss reflects Research and development - Balancing increase of 34% to $48.5M (expense), Stock-based Compensation in SGA increase of 24% to $6.1M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
50 Hampshire Street, 8Th Floor
02139
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com